New Delhi: The Lung World (WLD) – September 25 reminds us to think about the health of the lungs and increased lung disease; and demanding to overcome access to care that is not fulfilled to this disease.
In accordance with the global burden of disease data and other research studies, more than nine crore patients suffer from lung disease, only one crore has access to the management of the right lung care in India.
It seems that 90 percent of lung patients are deprived of access to lung care, which leads ahead, the accessibility gap of large treatment.
To fill this gap, Alkem Laboratories Ltd., on World Lung Day 2021, launched Pulmocare, a division to increase awareness, diagnosis, and management for lung disease such as asthma, COPD, allergies, sophisticated lung disease through various product.
For lung concern with the aim of bringing drastic changes in the accessibility of lung treatment in India by early diagnosis, better achieving and marked health promotion.
The cause of the burden of high lung disease has been identified as the basic ability of diagnostic tools such as spirometry, awareness of patients who are insufficient diseases, and the delay in the patient’s health reach.
This produces enormous health losses that lead to death and / or the service period is adjusted to disability (Daly).
Sandeep Singh, Managing Director, Alkem Laboratories Ltd., stated.
“Taking stocks to fill the large gap of lung accessibility for a larger population in India, we have decided to take a big leap to overcome the burden of large lung disease in this country by launching a comprehensive lung care division – Pulmocare.
With Alkemlaunch Pulmocare division, we will spread the awareness of this disease between patients and encourage them to use the right drug.
“Addressing, Sandeep confirms,” ​​Alchemy, for years, is always at the forefront of providing high-quality patient care, through innovation and patient-centric initiatives.
We have evolved as one of the most preferred partners for doctors in management infections, nutraceutical, gastric and pediatric care.
“Established in 1973 and headquartered in Mumbai, Alkem (NSE: Alcohes, BSE: 539523, Bloomberg: Alkem.in, Reuters: Alke.NS) is a leading Indian pharmaceutical company with global operations , Engage in the development, manufacture and sale of pharmaceutical and nutraceutical products.
The company produces branded generic, generic drugs, active pharmaceutical materials (fire) and nutraceutical, which are the IT market in India and the international market.
With a portfolio of more than 800 brands in India, alches are ranked fifth largest pharmaceutical company in India in terms of domestic sales (source: Iqvia March 2021).
The company also has a presence in more than 40 international markets, with the United States to become the main focus market.